Jasper Therapeutics - Class A (JSPR) closed at $13.37 on November 12, 2026, down 9.4% from the previous close, on volume of 32,407 shares (30-day average 355,882).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
Jasper Therapeutics Reports Majority Warrant Tender Offer Participation
TipRanks (Mon, 9-Nov 8:32 AM ET)
Jasper Therapeutics, Inc. Announces Results of the Offer to Purchase Relating to Its Warrants
Globe Newswire (Mon, 9-Nov 8:00 AM ET)
Jasper Therapeutics Announces 1-for-30 Reverse Stock Split
Globe Newswire (Wed, 4-Nov 8:00 AM ET)
Globe Newswire (Thu, 15-Oct 8:00 AM ET)
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
Globe Newswire (Wed, 7-Oct 8:00 AM ET)
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
Globe Newswire (Tue, 15-Sep 4:05 PM ET)
Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Wed, 9-Sep 8:00 AM ET)
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Fri, 14-Aug 11:00 AM ET)
Market Chameleon (Tue, 2-Dec 4:54 AM ET)
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
Jasper Therapeutics - Class A trades on the NASDAQ stock market under the symbol JSPR.
As of November 13, 2026, JSPR stock price climbed to $13.80 with 5,457 million shares trading.
JSPR has a beta of 2.96, meaning it tends to be more sensitive to market movements. JSPR has a correlation of 0.09 to the broad based SPY ETF.
JSPR has a market cap of $15.31 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, JSPR traded as high as $930.30 and as low as $9.45.
The top ETF exchange traded funds that JSPR belongs to (by Net Assets): VTI, VXF.
JSPR has underperformed the market in the last year with a price return of -74.0% while the SPY ETF gained +10.7%. JSPR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -44.2% and -13.5%, respectively, while the SPY returned -2.8% and -2.6%, respectively.
JSPR support price is $12.26 and resistance is $14.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JSPR shares will trade within this expected range on the day.
